Bristol-Myers Squibb Company
I · Analyse IA
En bref
Bristol-Myers Squibb discovers, develops, manufactures, and sells prescription medicines worldwide, focusing on cancer treatments (Opdivo, Yervoy, Breyanzi), immune system drugs (Orencia, Zeposia), blood disorder treatments (Reblozyl, Revlimid), and cardiovascular medicines (Eliquis) [Yahoo Finance]. The company sells through wholesalers, specialty pharmacies, hospitals, and government agencies across global markets [Yahoo Finance].
Bristol-Myers Squibb is a large pharmaceutical company that develops and sells drugs for cancer, immune diseases, heart conditions, and neurological disorders [Yahoo Finance]. The company generates $48.2B in annual revenue, maintains a $119B market cap, and is financially healthy with strong cash flow [Yahoo Finance]. Recent news highlights aggressive AI partnerships with Anthropic and Tempus AI to accelerate drug discovery, plus a major $1B manufacturing expansion in Houston [Yahoo Finance].
Bristol-Myers Squibb is financially healthy with strong profitability and solid cash generation, though revenue is flat year-over-year [Yahoo Finance].
Score Sentinellis
7.4/10
Financially healthy
Capitalisation boursière
$119.1B
Chiffre d'affaires (12 mois)
$48.2B
II · Actualités récentes
Ce qui a fait bouger le cours
6 stories · ranked by relevance
- macro2026-05-20
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
Yahoo Finance
- macro2026-05-19
How The Bristol Myers Squibb (BMY) Story Is Shifting Around Pipeline Hopes And Patent Risks
Simply Wall St
- macro2026-05-20
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery
Yahoo Finance
- macro2026-05-18
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts
Benzinga
- macro2026-05-19
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks
- macro2026-05-18
Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist
Simply Wall St
Premium · gratuit avec tout compte
Revenue is flat year-over-year at -0.2%, signaling potential challenges in maintaining growth momentum as key drug patents approach expiration [Yahoo Finance].
Risques
4
Opportunités
6
Signaux d'alerte
1
Direction
10
20 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Bristol-Myers Squibb Company
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 4 risques, 6 opportunités et 1 signal d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
- Export PDF pour la lecture hors ligne
III · Entreprises similaires
À lire également
Same sector · Healthcare or comparable health
L'ajouter à votre liste ?